By the BMA statistics, we also noted that CD56 contributes significantly to APL screening (Fig. 2), which was just mentioned as a low expression marker in the disease compared to other types of AML [11, 13, 14, 16–20]. This evidence concerns the gene NCAM1 and acute promyelocytic leukemia.